Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 1:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
Interventions
Total Knee Arthroplasty
Procedure
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
12
States / cities
Atlanta, Georgia • Boston, Massachusetts • Novi, Michigan + 8 more
Conditions
Macular Edema
Interventions
Dexamethasone Phosphate Ophthalmic
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

ISOVUE Comparative Trial

NCT07363759
Conditions
Lumbar Degenerative Disease, Lumbar Degenerative Disc Disease, Degenerative Spine
Interventions
ISOVUE 300 Observation, ISOVUE 300 Feedback
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Intravitreal Aflibercept Injection 2mg
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Music, Social Attention, and Dementia

NCT06768996
Conditions
Frontotemporal Dementia, Alzheimer Disease
Interventions
Synchronous Rhythm Production, Solo Rhythm Production
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 89 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Advanced Solid Tumors
Interventions
BMS-986484, Nivolumab, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Grand Rapids, Michigan + 2 more
Conditions
Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders
Interventions
QR-1123, Sham procedure
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Aurora, Colorado • Gainesville, Florida • Lexington, Kentucky + 2 more
Conditions
Age Related Macular Degeneration
Interventions
Subretinally injected RetinoStat
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
Conditions
Degenerative Joint Disease of the Ankle
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Degenerative Joint Disease, Osteoarthritis, Knee Injury, Trauma, Connective Tissue Disorder, Pain, Loss of Function
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
40 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Bernardino, California
Conditions
Age-Related Macular Degeneration
Interventions
Elamipretide
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Friedreich Ataxia
Interventions
CTI-1601, Placebo
Biological · Other
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Eatontown, New Jersey
Conditions
Cystoid Macular Edema
Interventions
Pegaptanib Sodium, Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Uveitis
Interventions
0.59 mg Fluocinolone Acetonide implant
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Completed Not applicable Interventional

Surgical Treatment for Hallux Rigidus

NCT01048450
Conditions
Hallux Limitus, Hallux Rigidus
Interventions
Joint Resection- Keller Procedure, Joint Fusion, Hemi-metallic Joint Implant
Radiation · Procedure
Lead sponsor
American College of Foot and Ankle Surgeons
Other
Eligibility
21 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Greeley, Colorado • Des Moines, Iowa • Scituate, Massachusetts + 3 more
Conditions
Alzheimer Disease
Interventions
[11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Study of Tau Imaging With the Use of [18F]MK-6240 Tracer

NCT04104659
Conditions
Alzheimer Disease
Interventions
MK 6240
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Macular Degeneration, Age-related Macular Degeneration
Interventions
Pazopanib eye drops and Allergen Refresh Plus eye drops
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Fargo, North Dakota • Austin, Texas
Conditions
Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
Interventions
[18F]-PI-2620
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting Not applicable Interventional Results available

2019-06 TRISCEND Study

NCT04221490
Conditions
Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Interventions
Transcatheter Tricuspid Valve Replacement
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Atlanta, Georgia + 9 more
Conditions
Friedreich Ataxia
Interventions
Buccal Swabs and Blood Draws
Diagnostic Test
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
20 participants
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Macular Degeneration, Age-related, Geographic Atrophy
Interventions
BI 771716, Pegcetacoplan, Sham comparator to BI 771716
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

NCT02951351
Conditions
Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection, Pain, Postoperative
Interventions
Proparacaine, Conjunctival culture
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Behavioral and Psychiatric Symptoms of Dementia, Alzheimer Disease, Lewy Body Disease, Frontotemporal Dementia
Interventions
Music therapy intervention, Personalized music CD
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania